secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2026-09-10T20:01:38+00:00
Accession:  0001104659-26-106699
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Yarrow Bioscience advances YB-101: FDA Fast Track, Phase 2a/2b trial started
----------------------------------------------------------------------------

- In-licensed YB-101 (anti-TSHR antibody) from GenSci in Dec 2025 for Graves' disease and thyroid eye disease outside China.
- FDA cleared IND for GD in March 2026; Fast Track designation granted May 20, 2026.
- Initiated combined Phase 2a/2b trial in June 2026; Phase 2a data expected H2 2027.
- Merger with Yarrow Bioscience Operating Company Corp. (formerly Yarrow Bioscience, Inc.) reflected in business update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/0001104659-26-106699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/tm2624937d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-106699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer